01 Connected Cell Counters Are Becoming Part of Automated Bioprocess Workflows The cell counting market is shifting from standalone bench instruments toward connected systems that fit directly into automated laboratory and bioprocess workflows. Modern counters combine image analysis, viability measurement, automated sample handling, electronic records, and software connectivity so results can move quickly into quality-control or process-monitoring systems. High-throughput formats also allow many samples to be processed with less operator involvement. In August 2026, ChemoMetec and Roche Diagnostics agreed to connect the XM30 cell counter with Roche’s Cedex Bio Analyzer for integrated bioprocess monitoring.
01 Cell Therapy Manufacturing Increases the Need for Precise Cell Enumeration Growth in cell and gene therapy manufacturing is increasing demand for accurate cell enumeration because the number and viability of cells directly affect process control and therapeutic dosing. Small errors can change concentration calculations or create inconsistency between manufacturing batches. In April 2025, The U.S. FDA approved Abeona Therapeutics’ ZEVASKYN, adding another commercial cell-based therapy to the expanding advanced-therapy manufacturing ecosystem.
01 Instrument and Compliance Costs Limit Adoption in Smaller Laboratories Advanced automated cell counters can be difficult for smaller laboratories to adopt because the total cost extends beyond the instrument itself. Fluorescence optics, validation packages, compliance software, service contracts, calibration materials, disposable counting slides, and staining reagents can add recurring expenses. Laboratories working under regulated conditions may also need installation qualification, operational qualification, user training, and documented software controls. These cost differences can slow replacement of manual methods in academic laboratories, small biotechnology companies, and diagnostic facilities with limited capital budgets.
01 Organoid Research Opens New Demand for Three-Dimensional Cell Quantification Organoids and other three-dimensional cell models are creating a new opportunity for cell counting technologies because conventional methods were designed mainly for dispersed single-cell suspensions. Researchers increasingly need to measure organoid number, size, growth, and treatment response across complex cultures. Manual microscope counting becomes slow and subjective when experiments contain many wells or irregular structures. Image-based counters and dedicated software can automate recognition of organoids and provide more consistent quantitative data. This creates demand for algorithms, imaging chambers, and analysis tools designed specifically for 3D biology. Suppliers that support organoid workflows can expand beyond routine cell viability into drug screening, disease modeling, and regenerative-medicine research.
01 Method-to-Method Variation Makes Reproducible Cell Counts Difficult Reproducibility remains a major challenge because different cell counting methods can produce different results from the same biological sample. Cell size, shape, clustering, debris, viability stains, sample mixing, dilution, and image-analysis settings can all influence the final count. Flow cytometry, imaging counters, Coulter methods, and manual hemocytometers also measure cells differently, making direct comparison difficult. NIST notes that suitable reference materials are limited for many cell types, so true accuracy can be hard to establish even when measurements appear precise.
June 2026 Thermo Fisher Scientific launched the Invitrogen EVOS S1000 Spatial Imaging System, expanding its cell analysis portfolio with advanced imaging capabilities that support automated cell counting and spatial biology research.
May 2026 Beckman Coulter Life Sciences introduced the CellMek SPS automated sample preparation system with enhanced workflow capabilities for high-throughput cell analysis and counting applications in clinical and research laboratories.
March 2026 Agilent Technologies expanded its cell analysis portfolio with new automated live-cell imaging and analysis solutions, strengthening capabilities for cell counting, viability assessment, and drug discovery workflows.
January 2026 Revvity expanded its research and development capabilities by opening a new life sciences innovation facility focused on advanced cell analysis, imaging, and automated laboratory technologies.